Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspen Pharmacare Holdings Ltd.

www.aspenpharma.com

Latest From Aspen Pharmacare Holdings Ltd.

Strides Exits Australia To ‘Double-Down’ On US Market

Strides founder Arun Kumar says he’s succeeded in putting the company back on the road to health after it shocked financial markets by swinging to a quarterly loss last year. But as part of the recovery plan, the company is selling its key Australia generic business to “double-down” on the US market.
Commercial Strategy

Aspen And Mylan Strike A Deal On Australia And New Zealand Portfolio

Mylan has bolstered its presence in key Australasian markets through a portfolio distribution arrangement with Aspen Pharma, which includes an option to buy in March 2019; the South African firm, on the other hand, is continuing to manage its portfolio in the markets, “allowing enhanced operational focus and removing complexity.”
Deals Health

Will Recent Excessive Pricing Cases Lay Down Precedent For Future?

The recent upsurge in cases of high drug prices being pursued by competition authorities in Europe could help to lay down some markers for judging what is an “excessive” price in future. At the same time, Brexit could see the UK and the EU begin to drift apart in terms of how they apply competition law to pricing issues.

Market Intelligence Outlook 2019

Will Recent Excessive Pricing Cases Lay Down Precedent For Future?

The recent upsurge in cases of high drug prices being pursued by competition authorities in Europe could help to lay down some markers for judging what is an “excessive” price in future. At the same time, Brexit could see the UK and the EU begin to drift apart in terms of how they apply competition law to pricing issues.

Market Intelligence Policy & Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register